This observation of cell signaling redundancy may explain the limited clinical response of ccRCC patients to mTOR-targeted therapies such as everolimus and temsirolimus (Kwiatkowski et al., 2016), suggesting that combinational therapy targeting both mTOR and MAPK/ERK pathways may be a more effective approach. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.